NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer Switzerland/Stans

Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer

July 19, 2021 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage

pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous

system (CNS) disorders, announces the appointment of Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal is a co-founder

and has over 30 years of experience as a physician and leading researcher in the field of sleep disorders and other CNS diseases.

a co-founder of NLS, Eric has already made enormous contributions to the Company with regard to our early work on Quilience and

Nolazol , and now he is able to fully devote his time and energy to advancing our drug pipeline and bringing value to patients, care

givers, and our shareholders," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "The time for Eric to join

us as our permanent Chief Scientific Officer couldn't be better as we recently submitted a series of patent applications, and our

early-stage pipeline now includes five compounds in addition to Quilience that have been issued patents or for which patent applications

am delighted to serve as the Company's Chief Scientific Officer where I can directly oversee the development of our pipeline of

repurposed compounds and new chemical entities designed to address rare and complex CNS disorders," said Dr. Konofal. "Our

lead product candidate, Quilience , is an exciting technology that we discovered has partial orexin-2 binding activity, and therefore,

offers potential to significantly improve the treatment of patients with narcolepsy. In addition to supporting this program, my focus

will be on the advancement of our earlier-stage compounds intended to treat diseases such as myalgic encephalomyelitis/chronic fatigue

syndrome (or ME/CFS) associated with COVID-19, Parkinson's disease, Alzheimer's disease, Huntington's disease, and

other sleep-wake cycle disorders including Central Disorders of Hypersomnolence (CDH) such as Kleine-Levin Syndrome. I am very proud

to have co-founded this Company, and I look forward to realizing its potential promise in helping patients with debilitating neurological

Konofal is a primary clinical and internationally renowned scientific researcher, and is an accomplished drug hunter and drug pipeline

developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr.

Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University

of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS),

and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Piti -Salp tri re University

Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology

of ADHD, and has conducted extensive research on the relationship between the brain and iron.

Konofal launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and

obtained the U.S. patent for mazindol in the treatment of ADHD. He wrote the scientific rational for Nolazol and discovered the

pharmacological profile of mazindol and its orexin-2 receptor binding properties.

Konofal has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases. His major scientific contributions

Konofal earned his M.D. degree and Ph.D. at the University of Paris (APHP).

NLS Pharmaceutics Ltd.

Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track

record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The

Company's lead product candidate, Quilience is a proprietary extended-release formulation of mazindol (mazindol ER), and

is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor

agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a

phase 2 study in the U.S. evaluating Nolazol (mazindol controlled-release) in adult subjects with ADHD. The study

met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and

in Europe for the treatment of narcolepsy.

press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using

forward-looking statements when it discusses its belief that the timing of the appointment as Chief Scientific Officer couldn't

be better, the potential diseases that Dr. Konofal intends to focus on advancing of the Company's earlier stage compounds and that

it looks forward to realizing its potential promise in helping patients with debilitating neurological conditions. These forward-looking

statements and their implications are based on the current expectations of the management of NLS only, and are subject to a number of

factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements:

changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its

clinical trials; NLS's products may not be approved by regulatory agencies, NLS's technology may not be validated as it progresses further

and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge

is essential to the development of its products; unforeseen scientific difficulties may develop with NLS's process; NLS's products may

wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical

settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS's patents may not be sufficient;

NLS's products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies,

products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results

or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by

law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances

after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties

affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F filed with the SEC, which is

available on the SEC's website, www.sec.gov.

Zwyer, CEO: +41 41 618 80 00

Rizzo: +1 908-229-7050